Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study compared the effectiveness of topical finasteride, oral finasteride, and topical minoxidil over 12 months in postmenopausal women with androgenetic alopecia, exploring their therapeutic effects on this population. Results are not reported in the abstract.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This review found that topical finasteride has similar efficacy to oral finasteride in treating male and female pattern hair loss, with fewer systemic side effects, mainly causing localized scalp reactions like irritation and erythema.

This study used computer simulations to evaluate the absorption of oral and topical finasteride for treating androgenetic alopecia, finding that topical applications resulted in lower plasma concentrations, suggesting potential viability as a treatment option.

In this study, topical finasteride 0.25% showed sustained effectiveness over 52 weeks, especially in the frontotemporal areas of men with androgenetic alopecia, while maintaining an excellent safety profile.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This abstract describes androgenetic alopecia, a common dermatological condition, and does not provide new clinical findings.

This study found topical finasteride and minoxidil both improved hair loss clinically and trichoscopically more effectively than spironolactone in women with female pattern hair loss.

This study found that among patients with stage III and IV androgenic alopecia, 83% of those using topical 5% minoxidil with topical 0.1% finasteride showed improved hair density, suggesting it may reduce the need for long-term oral finasteride.

This study found that the HPCH-based formulation P-08–016 may facilitate finasteride deposition in the dermis, potentially offering an alternative to systemic therapy by minimizing systemic absorption.

In this study, the addition of a topical gel containing growth-factor mimicking oligopeptides and other ingredients showed improved efficacy in subjects with androgenic alopecia using minoxidil or finasteride compared to drug treatment alone.

Using both minoxidil and finasteride together on the scalp works better for male hair loss than using either one alone.

A new topical finasteride formulation effectively promotes hair growth with fewer side effects.

This study found that Finasteride microemulsion gel significantly reduced acne lesions in men compared to a control treatment over three months.

In this study, researchers found that a propylene glycol-free and alcohol-reduced topical foam containing minoxidil and finasteride remained chemically, physically, and microbially stable for 180 days when stored properly at room temperature in light-resistant containers.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

In this large retrospective study, patients using compounded topical finasteride and minoxidil through a telehealth platform for male androgenetic alopecia reported high satisfaction and low incidence of side effects, with no need for higher care or treatment discontinuation due to adverse reactions.

This study found that the newly developed microarray patches for intradermal delivery of finasteride showed high drug content and significantly improved skin deposition compared to existing methods.

This study found that treating male pattern androgenetic alopecia with a combination of topical minoxidil and finasteride resulted in better outcomes for hair growth and density compared to using minoxidil alone.

A new microneedle system effectively delivers finasteride to treat hair loss.

This review finds preliminary evidence suggesting that topical finasteride may significantly reduce hair loss and increase hair counts in treating androgenetic alopecia, with a promising safety profile.

This review discusses the progress in research on topical formulations for treating alopecia, highlighting potential advantages of advanced formulation technologies but reporting no new clinical results.

Minoxidil sulfate gel can be used to treat hair loss.

This study found that using hollow mesoporous silica nanoparticles as carriers in a topical finasteride formulation significantly enhanced drug retention and hair regrowth in an AGA mouse model, suggesting a promising approach for treating androgenetic alopecia with reduced side effects.

This abstract provides no research findings or scientific content; it appears to be a website cookie policy and terms of use statement.